Quan Joanne
Known title: CHIEF MEDICAL OFFICERCIK: 0001670138
Associated companies
Transaction History
| MIRM | ▼ Sell | Open Market | 7,287 | $670K | 3/16/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 13,334 | — | 3/15/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,822 | $170K | 1/22/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 3,334 | — | 1/21/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 6,911 | $624K | 1/20/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 12,500 | — | 1/16/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 6,969 | $320K | 1/17/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 12,500 | — | 1/16/2025 | View on chart |
| MIRM | ▲ Buy | Grant | 118 | $2K | 11/8/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta
Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.